MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To judge a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Principal trial aims had been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, when one of https://nicolausq888coa1.topbloghub.com/profile